Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

D3S-003

Phase 1Small molecule

DD3 Bio (Wuxi) Co., Ltd

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

KRAS P.G12DRecruiting

KRAS P.G12DPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

KRAS P.G12D

NCT07456046

Clinical

Trials by Indication[1]

KRAS P.G12D1 trial

A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation

Recruiting·DD3 Bio (Wuxi) Co., Ltd·Phase 1·NCT07456046·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D3S-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D3S-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D3S-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — D3 Bio (Wuxi) Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DD3 Bio (Wuxi) Co., Ltd

Related News